Key result
Transcatheter tricuspid interventions show exponential volume growth alongside a ~60% reduction in in-hospital mortality.
Why the study?
Tricuspid regurgitation has gained substantial attention, but nationwide trends in the clinical usage of interventional therapies in Germany needed evaluation.
How have the usage and in-hospital outcomes of transcatheter tricuspid valve therapies evolved in real-world practice in Germany compared to clinical trials?
Observational (n=13,165)
Yes
How have the usage and in-hospital outcomes of transcatheter tricuspid valve therapies evolved in real-world practice in Germany compared to clinical trials?
Answers are grounded in this paper and cite their sources.
Real-world data from Germany demonstrates rapid, exponential adoption of transcatheter tricuspid valve interventions with declining in-hospital mortality, though mortality and length of stay remain higher than in highly selected clinical trial populations.
Importance: Tricuspid regurgitation (TR) has gained enormous attention in recent years. Objective: Here we aim to report the evolving usage of interventional therapies for TR in Germany. Design, settings and participants: We investigated all transcatheter tricuspid valve therapies in Germany (DRG-Statistics) from 2012 to 2023. From 2021 the differentiation between TEER, percutaneous annuloplasty and "other catheter-based interventions" became possible. We assessed comorbidities using ICD-10-GM data. Data from RCT studies were derived from trials’ main publication for TRISCEND II, TRILUMINATE pivotal and TRI.Fr. Results: We identified N=13,165 cases with an endovascular intervention of the tricuspid valve. In-depth characterization was eligible for all cases from 2016 (N=13,091). Cases increased from a total of 74 in 2012 to 2015 to 4298 cases in 2023 by an exponential rise (lm[log(n) ~ year]: β = 0.5; p = 4.79e-06). TEER was most frequently used (9,274/10,048 cases (92%) in 2021-2023). Median age was 81 years, 58% were female. Compared to TRI.FR and TRISCEND II trial, patients treated in Germany had a higher mean age. Patients had a median length of hospital stay of 8 days which was longer than in all three comparators. In-hospital mortality rate declined from >4% to 1.6% (TRILUMINATE pivotal: 0%; TRI.FR 0.6%). We further found that the in-hospital mortality was significantly higher in centers with a lower number of cases per year, but this effect was confounded by the year in which the case was registered. Conclusion and relevance: This first comprehensive real-world data analysis of percutaneous tricuspid valve treatment in Germany showed an exponential increase in procedures in Germany proving very rapid adoption of another novel transcatheter concept in structural heart disease treatment. Real-world intra-hospital mortality decreased over the last years but was still slightly higher than reported in trials.
No takes yet. Share an insight, caveat, or question.
Voran et al. (2025) conducted an observational in Tricuspid regurgitation (n=13,165). Transcatheter tricuspid valve therapies vs. Historical rates and RCT populations was evaluated on In-hospital mortality rate. Transcatheter tricuspid valve therapies in Germany increased exponentially to 4,298 cases in 2023, with in-hospital mortality declining to 1.6%.
Synapse has enriched 10 related papers. Consider them for comparative context: